The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | METIS: Tumor Treating Fields (TTFields) in patients with NSCLC and brain metastases
Minesh Mehta, MD, Miami Cancer Institute, Miami, FL, discusses findings from the Phase III METIS trial (NCT02831959), which evaluated the efficacy and safety of Tumor Treating Fields (TTFields) therapy in patients with non-small cell lung cancer (NSCLC) and brain metastases treated with stereotactic radiosurgery (SRS). Results demonstrated that TTFields significantly prolonged time to intracranial progression, improved quality of life, and did not negatively impact cognition. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Chimerix
Consulting or Advisory Role – Kazia Therapeutics; Mevion Medical Systems; Novocure; Telix Pharmaceuticals; Xoft; ZappRx
Patents, Royalties, Other Intellectual Property – WARF patent 14/934,27, TOPICAL VASOCONSTRITOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY
